News & Updates

Show Multimedia Only

Off-label targeted drugs improve survival in CTEPH

26 Jun 2024

Off-label pulmonary arterial hypertension (PAH)-targeted drugs may increase long-term survival in patients with chronic thromboembolic pulmonary hypertension (CTEPH), as shown in a study.

Off-label targeted drugs improve survival in CTEPH

26 Jun 2024

Sotorasib-panitumumab combo shows positive OS trend in mCRC

26 Jun 2024 by

The combination regimen comprising sotorasib and panitumumab demonstrates a trend towards an improvement in overall survival (OS) compared with investigator’s choice of therapy among patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC) who had progressed on systemic therapy, according to the OS analysis of the CodeBreak 300 trial presented at ASCO 2024.

Sotorasib-panitumumab combo shows positive OS trend in mCRC

26 Jun 2024

Sildenafil cream for female sexual arousal disorder may benefit only a subset of women

25 Jun 2024 by

Topical sildenafil cream appears to deliver promising outcomes for premenopausal women with sexual arousal disorder with or without concomitant decreased sexual desire, with increased arousal and reduced sexual distress, according to the results of an exploratory post hoc efficacy analysis of a phase IIb trial.

Sildenafil cream for female sexual arousal disorder may benefit only a subset of women

25 Jun 2024

One vs two sets of busulfan TDM show similar outcomes in alloHCT

25 Jun 2024

Outcomes of allogeneic hematopoietic cell transplant (alloHCT) do not differ in patients who underwent either one or two sets of busulfan therapeutic drug monitoring (TDM) sampling, reports a study.

One vs two sets of busulfan TDM show similar outcomes in alloHCT

25 Jun 2024

Hypersensitivity reactions to chemo, monoclonal antibodies offer clues in cancer management

24 Jun 2024

Identifying hypersensitivity reactions to anticancer chemotherapy and monoclonal antibodies may help clinicians improve management of patients with oncological diseases, suggests a study.

Hypersensitivity reactions to chemo, monoclonal antibodies offer clues in cancer management

24 Jun 2024

Vonoprazan trumps PPIs for treatment of grade C/D esophagitis

24 Jun 2024 by

Treatment with vonoprazan, a potassium competitive acid blocker (P-CAB), successfully starts and sustains the healing of Los Angeles (LA) grade C/D esophagitis as compared with proton pump inhibitor (PPI) and has moderate short- and long-term safety, according to a study. On the other hand, other P-CAB therapies need more evidence to prove their advantages.

Vonoprazan trumps PPIs for treatment of grade C/D esophagitis

24 Jun 2024

Drugs.com detects more drug–drug interactions in breast cancer patients

24 Jun 2024

A recent study has found more potential drug‒drug interactions in breast cancer patients receiving doxorubicin and cyclophosphamide regimen in the Drugs.com database than in the Lexicomp and Micromedex databases.

Drugs.com detects more drug–drug interactions in breast cancer patients

24 Jun 2024

No clear mortality benefit with continuous vs intermittent antibiotics in sepsis treatment

24 Jun 2024

In the treatment of critically ill patients with sepsis, continuous infusion of β-lactam antibiotics does not appear to significantly reduce 90-day mortality compared with intermittent infusions, according to the results of an open-label BLING III trial.

No clear mortality benefit with continuous vs intermittent antibiotics in sepsis treatment

24 Jun 2024

Densiron improves visual outcomes in eyes with primary RRD

23 Jun 2024 by

Densiron, a heavier-than-water endotamponade agent, may be used in the treatment of primary rhegmatogenous retinal detachment (RRD) in eyes with predominantly inferior retinal pathology and proliferative vitreoretinopathy (PVR) grade C, as shown by its higher anatomic success rates and improved visual outcomes relative to conventional light silicone oil (LSO), suggests a study.

Densiron improves visual outcomes in eyes with primary RRD

23 Jun 2024

Survodutide treatment for MASH with fibrosis scores high in mid-stage trial

21 Jun 2024 by

The investigational dual agonist of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor survodutide helps reduce the histological activity of metabolic dysfunction-associated steatohepatitis (MASH) as well as improve fibrosis, according to the phase II 1404-0043 trial.

Survodutide treatment for MASH with fibrosis scores high in mid-stage trial

21 Jun 2024

News & Updates

Filter by Specialty:

Specialty:

Off-label targeted drugs improve survival in CTEPH

Off-label targeted drugs improve survival in CTEPH

Sotorasib-panitumumab combo shows positive OS trend in mCRC

Sotorasib-panitumumab combo shows positive OS trend in mCRC

Sildenafil cream for female sexual arousal disorder may benefit only a subset of women

Sildenafil cream for female sexual arousal disorder may benefit only a subset of women

One vs two sets of busulfan TDM show similar outcomes in alloHCT

One vs two sets of busulfan TDM show similar outcomes in alloHCT

Hypersensitivity reactions to chemo, monoclonal antibodies offer clues in cancer management

Hypersensitivity reactions to chemo, monoclonal antibodies offer clues in cancer management

Vonoprazan trumps PPIs for treatment of grade C/D esophagitis

Vonoprazan trumps PPIs for treatment of grade C/D esophagitis

Drugs.com detects more drug–drug interactions in breast cancer patients

Drugs.com detects more drug–drug interactions in breast cancer patients

No clear mortality benefit with continuous vs intermittent antibiotics in sepsis treatment

No clear mortality benefit with continuous vs intermittent antibiotics in sepsis treatment

Densiron improves visual outcomes in eyes with primary RRD

Densiron improves visual outcomes in eyes with primary RRD

Survodutide treatment for MASH with fibrosis scores high in mid-stage trial

Survodutide treatment for MASH with fibrosis scores high in mid-stage trial